INSULET CORP

PODDNASDAQ

🏆 #922 by market capEarnings Oct 29US Equity

$132.85▼ $0.31 (−0.23%)

After hours · at close

🔔

Track PODD

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.2%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$9.20B

Small Cap

📈Revenue Growth (YoY)

+30.7%

High Growth

📊Gross Margin

71.1%

High

💵FCF Margin

9.8%

Moderate

⚖️P/S Ratio

3.1x

Fair

Otter Score

Fair

No chart data available for PODD.

Trading Snapshot

Day Range: $131.55 – $134.99
52-Week Range: $126.40 – $354.88
Volume: $5.48B
Avg Volume: $4.75B
Shares Outstanding: 69.3M
Next Earnings: Nov 20, 2026

Fundamentals Snapshot

Annual Revenue: $2.71B
Last Q Revenue: $802M
P/E Ratio: 25.4
P/S Ratio: 3.1x
EPS (TTM): $5.42
Dividend Yield: 0.00%
Dilution (1yr): −4.6%

Why Investors Own PODD

✓High-growth profile — revenue up +55.0% YoY with expanding US Equity exposure.
✓Healthy economics — 71% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INSULET CORP

PODD

Financial Trends

Revenue

$2.7B▲ +30.7% YoY

Gross Margin

71.6%▲ +2.6% YoY

Operating Income

$474M▲ +53.4% YoY

Free Cash Flow

$378M▲ +23.7% YoY

Shares Outstanding

70.7M▼ −4.6% YoY

Net Cash

−$335M▲ +$134M YoY

StockOtter · stockotter.space

About INSULET CORP

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

🦦